STOCK TITAN

Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Welcome to our dedicated page for Teva Pharmaceutical Industries American Depositary Shares news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharmaceutical Industries American Depositary Shares stock.

Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is a leading Israeli multinational pharmaceutical company headquartered in Tel Aviv, Israel. As the world's largest generic drug manufacturer, Teva plays a pivotal role in the global healthcare industry. The company derives approximately 50% of its sales from North America, contributing significantly to the total number of generic prescriptions in the United States.

Teva's extensive portfolio includes not only generic drugs but also active pharmaceutical ingredients (APIs) and proprietary pharmaceuticals. The company's operations are categorized into three main therapeutic areas:

  • Central Nervous System (CNS): Featuring notable products such as Copaxone, Ajovy, and Austedo, Teva addresses critical CNS disorders with innovative treatments.
  • Respiratory: Products like Qvar and ProAir contribute to Teva's robust respiratory medicine lineup, catering to patients with various respiratory conditions.
  • Oncology: Teva's oncology portfolio includes groundbreaking medicines such as Truxima, Herzuma, and Bendeka/Treanda, providing essential treatments for cancer patients.

In addition to its pharmaceutical products, Teva is a major player in active pharmaceutical ingredients, offering contract manufacturing services and owning Anda, a U.S.-based distributor of generic and specialty drugs.

Teva's global presence extends beyond North America, with significant operations in Europe, Japan, Russia, and its home country, Israel. The company's strategic partnerships and innovations keep it at the forefront of the pharmaceutical industry. Recent developments include advancements in biosimilars and innovative treatments.

Financially, Teva continues to maintain a strong position, focusing on growth and resilience amidst market challenges. The company is committed to improving patient health worldwide by providing high-quality, affordable medicines.

Rhea-AI Summary
Teva Pharmaceuticals announced that 92% of patients with Huntington's disease achieved optimal dosing with AUSTEDO using a 4-week patient titration kit. Additional results showed the efficacy and tolerability of AUSTEDO. AUSTEDO remains the only VMAT2 inhibitor with 3-year data for Huntington's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences
-
Rhea-AI Summary
Teva Pharmaceuticals announces efficacy and safety findings from the phase 3 RISE study, supporting the FDA approval of UZEDY as a long-acting injectable antipsychotic treatment for adults with schizophrenia. UZEDY significantly prolonged time to impending relapse by up to 5.0 times versus placebo, with once-monthly dosing showing an 80% decreased risk of relapse. The safety profile of UZEDY was consistent with other formulations of risperidone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
-
Rhea-AI Summary
Data from the UNITE study presented at the World Congress of Neurology shows that AJOVY® (fremanezumab) reduces migraine attacks and depression symptoms in migraine patients with major depressive disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
Rhea-AI Summary
Teva achieves 0.005% incident rate with FourKites' global carrier visibility solution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
Rhea-AI Summary
Teva Pharmaceutical Industries to release Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.37%
Tags
conferences earnings
-
Rhea-AI Summary
Sanofi and Teva Pharmaceuticals announce a collaboration to co-develop and co-commercialize asset TEV '574, a therapy for ulcerative colitis and Crohn's disease. Teva will receive an upfront payment of €469 million ($500 million) and up to €940 million ($1 billion) in development and launch milestones. Initial program results expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
none
Rhea-AI Summary
Teva Pharmaceutical Industries announces leadership changes. Sven Dethlefs to leave on Nov 17, 2023. Chris Fox appointed as head of Teva's U.S. Commercial Business. Fox brings 30 years of healthcare industry experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
Rhea-AI Summary
Teva Pharmaceutical Industries CEO to present at Morgan Stanley Global Healthcare Conference on September 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
conferences
-
Rhea-AI Summary
Teva Pharmaceuticals announces 16 data presentations at Psych Congress, highlighting AUSTEDO, UZEDY, TV-44749, and AJOVY. AUSTEDO XR and UZEDY received FDA approval. Positive potential for patients with TD, HD, and schizophrenia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
Rhea-AI Summary
Teva Pharmaceuticals reaches deferred prosecution agreement with the U.S. Department of Justice to settle price-fixing charges. Teva will pay a fine of $225 million over five years, donate $50 million worth of products, and divest one generic product. Former employee involved in bidding agreement. Teva emphasizes commitment to compliance and delivering quality medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none

FAQ

What is the current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?

The current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is $22.09 as of December 20, 2024.

What is the market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?

The market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is approximately 24.7B.

What does Teva Pharmaceutical Industries Limited specialize in?

Teva specializes in generic drugs, active pharmaceutical ingredients, and proprietary pharmaceuticals.

Where is Teva headquartered?

Teva is headquartered in Tel Aviv, Israel.

What are some of Teva's key products?

Key products include Copaxone, Ajovy, Austedo, Qvar, ProAir, Truxima, Herzuma, and Bendeka/Treanda.

In which regions does Teva operate?

Teva operates in North America, Europe, Japan, Russia, and Israel.

How much of Teva's sales come from North America?

Approximately 50% of Teva's sales come from North America.

What therapeutic areas does Teva focus on?

Teva focuses on central nervous system, respiratory, and oncology therapeutic areas.

What is Anda?

Anda is a U.S.-based distributor of generic and specialty drugs owned by Teva.

Does Teva offer contract manufacturing services?

Yes, Teva offers contract manufacturing services.

What role does Teva play in the U.S. generic prescription market?

Teva accounts for a high-single-digit percentage of the total number of generic prescriptions in the U.S.

What recent advancements has Teva made?

Teva has made advancements in biosimilars and innovative treatments across its therapeutic areas.

Teva Pharmaceutical Industries Limited American Depositary Shares

NYSE:TEVA

TEVA Rankings

TEVA Stock Data

24.72B
1.13B
0%
57.83%
1.87%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
TEL AVIV